185 related articles for article (PubMed ID: 24465589)
1. The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.
Puig-Domingo M; Luque RM; Reverter JL; López-Sánchez LM; Gahete MD; Culler MD; Díaz-Soto G; Lomeña F; Squarcia M; Mate JL; Mora M; Fernández-Cruz L; Vidal O; Alastrué A; Balibrea J; Halperin I; Mauricio D; Castaño JP
PLoS One; 2014; 9(1):e85527. PubMed ID: 24465589
[TBL] [Abstract][Full Text] [Related]
2. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
[TBL] [Abstract][Full Text] [Related]
3. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
[TBL] [Abstract][Full Text] [Related]
4. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
[TBL] [Abstract][Full Text] [Related]
5. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells.
Molè D; Gentilin E; Ibañez-Costa A; Gagliano T; Gahete MD; Tagliati F; Rossi R; Pelizzo MR; Pansini G; Luque RM; Castaño JP; degli Uberti E; Zatelli MC
Endocrine; 2015 Nov; 50(2):442-52. PubMed ID: 25854304
[TBL] [Abstract][Full Text] [Related]
6. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells.
Durán-Prado M; Gahete MD; Hergueta-Redondo M; Martínez-Fuentes AJ; Córdoba-Chacón J; Palacios J; Gracia-Navarro F; Moreno-Bueno G; Malagón MM; Luque RM; Castaño JP
Oncogene; 2012 Apr; 31(16):2049-61. PubMed ID: 21927030
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin Receptor Splicing Variant
Fuentes-Fayos AC; G-García ME; Pérez-Gómez JM; Peel A; Blanco-Acevedo C; Solivera J; Ibáñez-Costa A; Gahete MD; Castaño JP; Luque RM
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163067
[TBL] [Abstract][Full Text] [Related]
8. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
[TBL] [Abstract][Full Text] [Related]
9. Cerebellar metastasis of papillary thyroid carcinoma detected with somatostatin receptor scintigraphy.
Czepczyński R; Wyszomirska A; Gryczyńska M; Szczepanek-Parulska E; Ruchała M
Endokrynol Pol; 2018; 69(1):24-27. PubMed ID: 29319129
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin analogs in the treatment of medullary thyroid carcinoma.
Díez JJ; Iglesias P
J Endocrinol Invest; 2002 Oct; 25(9):773-8. PubMed ID: 12398235
[TBL] [Abstract][Full Text] [Related]
11.
Camargo Barros-Filho M; Barreto Menezes de Lima L; Bisarro Dos Reis M; Bette Homem de Mello J; Moraes Beltrami C; Lopes Pinto CA; Kowalski LP; Rogatto SR
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884810
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
13. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors.
Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772
[TBL] [Abstract][Full Text] [Related]
14. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer.
Ryder M; Ghossein RA; Ricarte-Filho JC; Knauf JA; Fagin JA
Endocr Relat Cancer; 2008 Dec; 15(4):1069-74. PubMed ID: 18719091
[TBL] [Abstract][Full Text] [Related]
15. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I
Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.
Papotti M; Kumar U; Volante M; Pecchioni C; Patel YC
Clin Endocrinol (Oxf); 2001 May; 54(5):641-9. PubMed ID: 11380495
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor subtype expression in cells of the rat immune system during adjuvant arthritis.
ten Bokum AM; Lichtenauer-Kaligis EG; Melief MJ; van Koetsveld PM; Bruns C; van Hagen PM; Hofland LJ; Lamberts SW; Hazenberg MP
J Endocrinol; 1999 Apr; 161(1):167-75. PubMed ID: 10194540
[TBL] [Abstract][Full Text] [Related]
18. The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.
Gahete MD; Rincón-Fernández D; Durán-Prado M; Hergueta-Redondo M; Ibáñez-Costa A; Rojo-Sebastián A; Gracia-Navarro F; Culler MD; Casanovas O; Moreno-Bueno G; Luque RM; Castaño JP
Oncotarget; 2016 Sep; 7(37):60110-60122. PubMed ID: 27507050
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
[TBL] [Abstract][Full Text] [Related]
20. The clinical course of poorly differentiated thyroid carcinoma (insular carcinoma) - own observations.
Walczyk A; Kowalska A; Sygut J
Endokrynol Pol; 2010; 61(5):467-73. PubMed ID: 21049460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]